Truncating FGFR2 exon 18 mutations, such as the FGFR2 frameshift variant seen in Tumor 3, are oncogenic and recurrent in cholangiocarcinoma and gastroesophageal and breast carcinoma and confer sensitivity to FGFR inhibition [18]. Here, FGFR2 is linked to cholangiocarcinoma.